Candel Therapeutics (CADL) EBT: 2020-2024
Historic EBT for Candel Therapeutics (CADL) over the last 5 years, with Dec 2024 value amounting to -$30.2 million.
- Candel Therapeutics' EBT rose 31.61% to -$5.4 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$33.7 million, marking a year-over-year increase of 3.54%. This contributed to the annual value of -$30.2 million for FY2024, which is 10.44% up from last year.
- Latest data reveals that Candel Therapeutics reported EBT of -$30.2 million as of FY2024, which was up 10.44% from -$33.7 million recorded in FY2023.
- Candel Therapeutics' EBT's 5-year high stood at -$13.7 million during FY2020, with a 5-year trough of -$35.2 million in FY2022.
- Moreover, its 3-year median value for EBT was -$33.7 million (2023), whereas its average is -$33.0 million.
- As far as peak fluctuations go, Candel Therapeutics' EBT plummeted by 88.18% in 2021, and later grew by 10.44% in 2024.
- Over the past 5 years, Candel Therapeutics' EBT (Yearly) stood at -$13.7 million in 2020, then tumbled by 88.18% to -$25.8 million in 2021, then tumbled by 36.59% to -$35.2 million in 2022, then rose by 4.25% to -$33.7 million in 2023, then climbed by 10.44% to -$30.2 million in 2024.